tbuckley/cabot-search huggingface dataset:
Abstract 13832: GPR39 is a High Affinity Vascular Smooth Muscle Receptor for P450 Eicosanoids
Authors: Nabil Alkayed, Zhiping Cao, Zu Yuan Qian, Fuchun Xie, Bingbing Li, Xiangshu Xiao, Anthony Barnes, Sanjiv Kaul
Journal: Circulation (2016)

Epoxyeicosatrienoic (EETs) and hydroxyeicosatetraenoic acids (HETEs) are endogenous vasoactive P450 eicosanoids that play important roles in cardiovascular physiology and disease, but their mechanisms of action are not fully understood. We developed a clickable photo-crosslinking probe (EET-P) based on EETs regio-isomer 14,15-EET, which allowed us to purify and enrich 14,15-EET binding proteins in mouse heart vascular smooth muscle cells (VSMCs). Proteomic analysis generated a list of proteins bound by EET-P that included the orphan G-protein coupled receptor 39 (GPR39). Consistent with the molecular weight of GPR39, sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) analysis revealed a prominent ~50 kD protein crosslinked to EET-P, and pretreatment with either 14,15-EET or its antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (14,15-EEZE) completely displaced EET-P binding. Heterologous expression of GPR39 but not a control plasmid in HEK293 cells conferred responsiveness to both 14,15-EET and 15-HETE, as assayed by extracellular-regulated kinase (ERK) activation. Immuno-histochemical analysis localized GPR39 expression in both mouse heart micro-vessels and primary cultured VSMCs. Live-cell imaging of VSMC intracellular calcium ([Ca 2+ ]i) revealed a dual and antagonistic regulatory mechanism in which 15-HETE induces and 14,15-EET suppresses VSMC calcium transients. Short hairpin RNA (shRNA) knockdown of GPR39 in VSMCs was sufficient to abolish effects of both 15-HETE and 14,15-EET on VSMC calcium. Our results identify GPR39 as a high-affinity, lipid-sensing GPCR antagonistically regulated by two endogenous P450 eicosanoids with opposing actions on VSMC calcium, and offer a unique window into multi-ligand GPCRs and their role in integrating the multitude of hormonal signals to regulate local tissue function and response to disease state.
Brote de sarampión en la región Provence-Alpes-Côte d’Azur, Francia, Enero-Julio 2003
Authors: C Six, F Franke, K Mantey, C Zandotti, F Freymuth, F Wild, I Parent du Châtelet, P Malfait
Journal: Eurosurveillance (2005)

A finales de mayo de 2003, el laboratorio de virologia del Centro hospitalario de Marsella informo al Instituto de Salud Publica frances que existian cinco casos confirmados de sarampion en jovenes adultos que vivian en Marsella. Se llevo a cabo una encuesta por la Unidad interregional de epidemiologia Sur en varios servicios sanitarios comunitarios y hospitalarios, para determinar la circulacion del virus en la region Provence-Alpes-Cote d’Azur (PACA). La investigacion permitio identificar 259 casos: 183 casos clinicos, 74 casos confirmados serologicamente y dos casos con vinculo epidemiologico. Los primeros casos fueron identificados durante los seis primeros meses de 2003, con un pico en Abril. Este brote de sarampion en la region PACA fue favorecida por la escasa cobertura vacunal, que creo grupos de poblacion susceptibles. El numero de casos fue probablemente superior al identificado. Esta investigacion puso de manifiesto las limitaciones del sistema de vigilancia del sarampion en Francia: la red centinela no habia detectado ningun caso en este periodo. Francia debe alcanzar el objetivo de la OMS de erradicacion del sarampion en 2010 y las herramientas de vigilancia deben ser las ya utilizadas en la mayoria de los paises mas adelantados en ese proceso de erradicacion. Para alcanzar este fin, la Direccion General de la Salud designo un grupo de trabajo con el objetivo de proponer un plan nacional para la interrupcion de la transmision autoctona del sarampion en Francia.
Effects of Cryotherapy on Objective and Subjective Symptoms of Paclitaxel-Induced Neuropathy: Prospective Self-Controlled Trial
Authors: Akiko Hanai, Hiroshi Ishiguro, Takashi Sozu, Moe Tsuda, Ikuko Yano, Takayuki Nakagawa, Satoshi Imai, Yoko Hamabe, Masakazu Toi, Hidenori Arai, Tadao Tsuboyama
Journal: JNCI Journal of the National Cancer Institute (2017)

Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting and disabling side effect of taxane anticancer agents. We prospectively evaluated the efficacy of cryotherapy for CIPN prevention. Breast cancer patients treated weekly with paclitaxel (80 mg/m2 for one hour) wore frozen gloves and socks on the dominant side for 90 minutes, including the entire duration of drug infusion. Symptoms on the treated sides were compared with those on the untreated (nondominant) sides. The primary end point was CIPN incidence assessed by changes in tactile sensitivity from pretreatment baseline in a monofilament test at a cumulative dose of 960 mg/m2. We also assessed thermosensory deficits, subjective symptoms (Patient Neuropathy Questionnaire [PNQ]), manipulative dexterity, and the time to events and hazard ratio by PNQ. All statistical tests were two-sided. Among the 40 patients, four did not reach the cumulative dose (due to the occurrence of pneumonia, severe fatigue, severe liver dysfunction, and macular edema), leaving 36 patients for analysis. None dropped out due to cold intolerance. The incidence of objective and subjective CIPN signs was clinically and statistically significantly lower on the intervention side than on the control (hand: tactile sensitivity = 27.8% vs 80.6%, odds ratio [OR] = 20.00, 95% confidence interval [CI] = 3.20 to 828.96, P < .001; foot: tacile sensitivity = 25.0% vs 63.9%, OR = infinite, 95% CI = 3.32 to infinite, P < .001; hand: warm sense = 8.8% vs 32.4%, OR = 9.00, 95% CI = 1.25 to 394.48, P = .02; foot: warm sense: 33.4% vs 57.6%, OR = 5.00, 95% CI = 1.07 to 46.93, P = .04; hand: PNQ = 2.8% vs 41.7%, OR = infinite, 95% CI = 3.32 to infinite, P < .001; foot: PNQ = 2.8% vs 36.1%, OR = infinite, 95% CI = 2.78 to infinite, P < .001; hand: hazard ratio [HR] = 0.13, 95% CI = 0.05 to 0.34; foot: HR = 0.13, 95% CI = 0.04 to 0.38, dexterity mean delay = −2.5 seconds, SD = 12.0 seconds, vs + 8.6 seconds, SD = 25.8 seconds, P = .005). Cryotherapy is useful for preventing both the objective and subjective symptoms of CIPN and resultant dysfunction.
Epidémiologie et réponses au problème croissant de la tuberculose à Londres
Authors: D Antoine, H Maguire, A Story
Journal: Eurosurveillance (2006)

Dans les pays a faible incidence de tuberculose, comme en Angleterre et au Pays de Galles, , la tuberculose tend a se concentrer dans des sous-groupes de population, et est essentiellement un probleme dans les grandes agglomerations. En 2003, pres de la moitie des cas de tuberculose declares en Angleterre et Pays de Galles provenaient de Londres, ou l’incidence etait presque cinq fois superieure a celle du reste du pays. Alors que la plus forte proportion de cas survient chez des personnes nees a l’etranger, une importante epidemie de tuberculose resistante aux traitements a confirme l’existence actuelle d’une transmission active parmi des groupes marginalises tels que les personnes sans domicile fixe, les usagers de drogues et les prisonniers. L’augmentation des taux de maladie et des niveaux de resistance combine au fait que la maladie soit concentree dans des groupes difficiles a atteindre, representent un defi majeur pour le controle de la tuberculose dans la ville. Pour repondre aux changements de l’epidemiologie de la tuberculose observes ces dernieres annees, les services de soins et de controle sont en cours de restructuration, la surveillance a ete renforcee avec la mise en place du registre londonien de TB, et l’efficacite du depistage radiologique digital mobile pour les populations a risque telles que les sans-abri et les prisonniers est cours d’evaluation. A Londres, la tuberculose est loin d’etre sous controle et beaucoup reste a faire. Les services sanitaires et sociaux doivent s’adapter aux besoins des groupes les plus touches. Cela requiert des ameliorations soutenues de la surveillance de la tuberculose ainsi que de l’acces aux soins et de la detection des cas. Le diagnostic rapide des cas doit etre assure ainsi qu’un accompagnement social actif pour les personnes entamant un traitement.
Interaction between ring sideroblasts and treatment with hypomethylating agents (HMA) in patients with refractory anemia with ring sideroblasts.
Authors: Rama Nanah, Darci Zblewski, Rong He, Phuong L. Nguyen, Naseema Gangat, Kebede Begna, Michelle A. Elliott, William J. Hogan, Mrinal Patnaik, Mark Robert Litzow, Aref Al-Kali
Journal: Journal of Clinical Oncology (2017)

e18559 Background: Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms defined by ineffective hematopoiesis, dysplastic morphologic features, and variable risks of progression to acute myeloid leukemia (AML). Refractory anemia with ring sideroblasts (RARS) is a subtype of MDS defined by &lt; 5% basts and &gt; 15% ring sideroblasts (per 2008 WHO). Because RARS is a lower risk disease which does not frequently require HMA therapy, very little is known about the effects of HMA on RARS. Methods: A total of 1325 MDS patients’ data from 1993-2016 at Mayo Clinic were reviewed after appropriate IRB approval was obtained. All cases had their bone marrow slides reviewed at our center. Patients were considered for our study if they received HMA for their RARS. Response was identified based on MDS IWG 2006 criteria. Prognostic factors were analyzed by univariate and multivariate analyses. Survival estimates were calculated using Kaplan-Meier curves. Results: 168 of the initial 1325 patient were RARS (14%); only 14 (8%) were treated with HMA. Median age was 72 years (range, 51-85); half were males, with median overall survival of 91.3 months. The median number of ring sideroblasts (RS) at diagnosis was 40% (range 10-85%). Of the 14 patients, 11 (79%) received azacitidine (AZA), 2 (14%) decitabine (DAC) and one received both (7%). The median number of cycles for AZA was 6.5 (range, 2-28) vs 6 cycles for DAC (range, 1-24). Of the 14 patients receiving HMA, only 3 responded (21%) achieving hematologic improvement. All 3 responders received AZA. 6 of the 14 RARS patients (43%) had their bone marrow biopsy repeated after HMA therapy, 3 of whom were among the responders to AZA therapy and 3 were non-responders. In 5 patients, ring sideroblasts decreased after HMA therapy by a median of 15% (range 0-80); they remained the same in 1 patient; one patient who had developed AML had a decrease in RS from 85% to 5%. Conclusions: RARS is a low-risk subtype of MDS that is infrequently treated with HMA (8% in our study). Response rate to HMA (21%) was inferior to known rates in MDS. HMA therapy seems to decrease the number of ring sideroblasts irrespective of response. RARS patients should be treated on clinical trials if available.
Association of an Electroencephalography-Based Risk Score With Seizure Probability in Hospitalized Patients
Authors: Aaron F. Struck, Berk Ustun, Andres Rodriguez Ruiz, Jong Woo Lee, Suzette M. LaRoche, Lawrence J. Hirsch, Emily J. Gilmore, Jan Vlachy, Hiba Arif Haider, Cynthia Rudin, M. Brandon Westover
Journal: JAMA Neurology (2017)

Continuous electroencephalography (EEG) use in critically ill patients is expanding. There is no validated method to combine risk factors and guide clinicians in assessing seizure risk.To use seizure risk factors from EEG and clinical history to create a simple scoring system associated with the probability of seizures in patients with acute illness.We used a prospective multicenter (Emory University Hospital, Brigham and Women's Hospital, and Yale University Hospital) database containing clinical and electrographic variables on 5427 continuous EEG sessions from eligible patients if they had continuous EEG for clinical indications, excluding epilepsy monitoring unit admissions. We created a scoring system model to estimate seizure risk in acutely ill patients undergoing continuous EEG. The model was built using a new machine learning method (RiskSLIM) that is designed to produce accurate, risk-calibrated scoring systems with a limited number of variables and small integer weights. We validated the accuracy and risk calibration of our model using cross-validation and compared its performance with models built with state-of-the-art logistic regression methods. The database was developed by the Critical Care EEG Research Consortium and used data collected over 3 years. The EEG variables were interpreted using standardized terminology by certified reviewers.All patients had more than 6 hours of uninterrupted EEG recordings.The main outcome was the average risk calibration error.There were 5427 continuous EEGs performed on 4772 participants (2868 men, 49.9%; median age, 61 years) performed at 3 institutions, without further demographic stratification. Our final model, 2HELPS2B, had an area under the curve of 0.819 and average calibration error of 2.7% (95% CI, 2.0%-3.6%). It included 6 variables with the following point assignments: (1) brief (ictal) rhythmic discharges (B[I]RDs) (2 points); (2) presence of lateralized periodic discharges, lateralized rhythmic delta activity, or bilateral independent periodic discharges (1 point); (3) prior seizure (1 point); (4) sporadic epileptiform discharges (1 point); (5) frequency greater than 2.0 Hz for any periodic or rhythmic pattern (1 point); and (6) presence of "plus" features (superimposed, rhythmic, sharp, or fast activity) (1 point). The probable seizure risk of each score was 5% for a score of 0, 12% for a score of 1, 27% for a score of 2, 50% for a score of 3, 73% for a score of 4, 88% for a score of 5, and greater than 95% for a score of 6 or 7.The 2HELPS2B model is a quick accurate tool to aid clinical judgment of the risk of seizures in critically ill patients.
3-weekly or weekly cisplatin concurrently with radiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck: A multicentre, retrospective analysis
Authors: S.I. Rothschild, S. Helfenstein, O. Riesterer, U.R. Meier, A. Papachristofilou, B. Kasenda, M. Pless
Journal: Annals of Oncology (2017)
Risk of recurrence prediction and optimum treatment planning for early stage breast cancer patients: A cost-effective, accurate and broad based solution for Asia
Authors: S. Somashekhar, M.M. Bakre, C. Ramkumar, C. Basavaraj, A. Arun Kumar, L. Madhav, C. Prakash, N. Naidu
Journal: Annals of Oncology (2017)
Treatment patterns, clinical outcomes and prognostic factors of visceral angiosarcoma (V-AS): A report from the Asian Sarcoma Consortium (ASC)
Authors: A. Pang, R. Ngan, S.H. Tan, T. Hirose, M. Endo, M. Farid, W.L. Goh, H.H. Loong, S. Mingmalairak, C.-C. Chang, S. Teo, M.M. Maw, A.K.C. Leung, J.C. Chan, M.E. Puhaindran, A. Kawai, W.-W.W. Chen, R. Quek, V. Sriuranpong
Journal: Annals of Oncology (2017)
Early T-Cell Precursor Acute Lymphoblastic Leukemia (ETP-ALL) Is a High-Risk Subtype in Adults
Authors: Nitin Jain, Audrey Lamb, Susan M. O'Brien, Farhad Ravandi, Marina Konopleva, Elias Jabbour, Zhuang Zuo, Jeffrey L. Jorgensen, Pei Lin, Sherry Pierce, Deborah A Thomas, Michael Rytting, Gautam Borthakur, Tapan Kadia, Jorge E. Cortes, Hagop M. Kantarjian, Joseph D Khoury
Journal: Blood (2015)
VENTANA (SOLTI-1501): Antiproliferative effect of the addition of oral metronomic vinorelbine to endocrine therapy in luminal/HER2-negative early breast cancer: A window of opportunity trial
Authors: B. Adamo, J.A. Perez Fidalgo, E. Ciruelos, M. Vidal, S. Blanch, A. Lopez, P. Gomez Pardo, L. Murillo, K. Amillano, N. Martínez Jañez, X. Gonzalez, J. Canes, A. Prat
Journal: Annals of Oncology (2017)
Avelumab treatment of metastatic urothelial carcinoma (mUC) in the phase 1b JAVELIN solid Tumor study: updated analysis with ≥6 months of follow-up in all patients
Authors: A.B. Apolo, J. Ellerton, J.R. Infante, M. Agrawal, M.S. Gordon, R. Aljumaily, C.D. Britten, L. Dirix, K-W. Lee, M.H. Taylor, P. Schöffski, D. Wang, A. Ravaud, A. Gelb, J. Xiong, G. Rosen, M.R. Patel
Journal: Annals of Oncology (2017)
Epidémie d’oreillons en Suède, février-avril 2004
Authors: B Sartorius, P Penttinen, J Nilsson, K Johansen, K Jönsson, M Arneborn, M Löfdahl, J Giesecke
Journal: Eurosurveillance (2005)

Entre le 24 fevrier et le 26 avril 2004, quarante deux cas suspects d’oreillons ont ete declares en Suede dans la region de Vastra Gotaland. Une etude descriptive de cas a ete realisee. Une enquete a ete menee par telephone et l’efficacite vaccinale a ete calculee en utilisant la methode administrative. Soixante quatorze pour cent (31/42) des cas suspects ont pu etre interroges par telephone. Huit des 42 prelevements analyses par test ELISA etaient positifs ou indetermines pour les IgM des oreillons. Le genome du virus des oreillons a ete identifie dans les echantillons de salive de 21 cas sur 42 (50%). Un sequencage genomique realise sur onze echantillons a confirme la presence du virus des oreillons. Les cas provenaient principalement de deux petites villes. Huit des 19 cas ayant developpe une tumefaction bilaterale etaient lies a une de ces villes. L’âge median des cas interroges etait de 43 ans (de 5 a 88). Six cas ont ete hospitalises, dont cinq avaient plus de 30 ans. L’incidence etait la plus elevee dans le groupe d’âge de 35 a 44 ans. L’efficacite vaccinale a ete estimee a 65% pour une dose et 91% pour deux doses. 
Cette etude descriptive montre l’augmentation de l’âge des cas d’oreillons avec une couverture vaccinale accrue. L’efficacite vaccinale etait particulierement elevee pour la vaccination en deux doses. L’administration d’une seconde dose est importante, compte-tenu des nombreux echecs, decrits dans la litterature, des immunisations primaires contre les oreillons. Il est essentiel de prendre des mesures plus radicales afin d’eviter une accumulation de personnes plus âgees susceptibles presentant un risque accru de complications.
PROFILER 02 - A multicentric, prospective cohort study aiming to evaluate the added value of a large molecular profiling panel (315 cancer-related gene panel [FoundationOne]) versus a limited molecular profiling panel (74 cancer-related gene panel [CONTROL]) in advanced solid tumours
Authors: J-Y Blay, V. Corset, C. Mastier, I. Treilleux, C. Le Tourneau, A. Italiano, J.P. Delord, V. Attignon, Q. Wang, C. Baudet, E. Sohier, M. Bernardin, L. Ben Abdesselem, A. D'argenio, V. Haddad, P. Saintigny, L. Perrier, S. Chabaud, D. Perol, O. Trédan
Journal: Annals of Oncology (2017)
De l’évaluation à l’assurance qualité en continu des systèmes de surveillance
Authors: G Krause
Journal: Eurosurveillance (2006)

Les systemes de surveillance ont ete decrits comme les « nerfs » de la sante publique, avec des bras afferents pour l’accueil d’informations, des « corps cellulaires » ou elles sont analysees et des bras efferents dont le role est de mettre en œuvre des a
Prognosis after loco-regional recurrence of breast cancer: 35 years longitudinal data from the Stockholm cancer register
Authors: C. Falato, L. Eriksson, A. Sofiadis, S.K. Taylor, A. Nordblom, I. Fredriksson, J. Hartman, J. Bergh, T. Foukakis
Journal: Annals of Oncology (2017)
Salmonela enteritidis na Europa Ocidental 1995-98 – um relatório de vigilância da Enter-net
Authors: I. S.T. Fisher
Journal: Eurosurveillance (1999)

A Salm-net, atraves da base de dados de salmonelas, identificou, na Europa Ocidental um declinio na incidencia de infeccoes por Salmonella enteritidis entre 1993 e 1995, quando o numero de isolamentos de S. enteritidis diminuiu de 37 647 para 31 482 (1). Esta diminuicao de 16% foi referida por sete laboratorios nacionais de referencia com dados disponiveis. No entanto, em meados de 1997, constatou-se que as notificacoes deste serotipo estavam a aumentar rapidamente (2). Dados de 12 paises, agora disponiveis em relacao ao periodo 1995 a 1998, mostram que esse ressurgimento actualmente desapareceu (figura).
A Phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours, hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer (BC; +/-endocrine therapy), or non-small-cell lung cancer (NSCLC)
Authors: A. Prat, D. Yee, M.P. Sablin, H. Iwata, E.L. Johnston, T. Bogenrieder, J. Serra, K. Stucke-Straub, P. Lo Russo
Journal: Annals of Oncology (2017)
Plasma Concentrations of Per- and Polyfluoroalkyl Substances at Baseline and Associations with Glycemic Indicators and Diabetes Incidence among High-Risk Adults in the Diabetes Prevention Program Trial
Authors: Andres Cardenas, Diane R. Gold, Russ Hauser, Ken P. Kleinman, Marie-France Hivert, Antonia M. Calafat, Xiaoyun Ye, Thomas F. Webster, Edward S. Horton, Emily Oken
Journal: Environmental Health Perspectives (2017)

Background: Several per- and polyfluoroalkyl substances (PFAS) are ubiquitous anthropogenic pollutants almost universally detected in humans. Experimental evidence indicates that PFAS alter glucose metabolism and insulin secretion. However, epidemiological studies have yielded inconsistent results. Objective: We sought to examine associations between plasma PFAS concentrations, glycemic indicators, and diabetes incidence among high-risk adults. Methods: Within the Diabetes Prevention Program (DPP), a trial for the prevention of type 2 diabetes among high-risk individuals, we quantified baseline plasma concentrations of nine PFAS among 957 participants randomized to a lifestyle intervention or placebo. We evaluated adjusted associations for plasma PFAS concentrations with diabetes incidence and key glycemic indicators measured at baseline and annually over up to 4.6 y. Results: Plasma PFAS concentrations were similar to those reported in the U.S. population in 1999–2000. At baseline, in cross-sectional analysis, a doubling in plasma perfluorooctanesulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) concentrations was associated with higher homeostatic model assessment of insulin resistance (HOMA-IR) [βPFOS=0.39; 95% confidence interval (CI): 0.13, 0.66; βPFOA=0.64; 95% CI: 0.34, 0.94], β-cell function (HOMA-β) (βPFOS=9.62; 95% CI: 1.55, 17.70; βPFOA=15.93; 95% CI: 6.78, 25.08), fasting proinsulin (βPFOS=1.37 pM; 95% CI: 0.50, 2.25; βPFOA=1.71 pM; 95% CI: 0.72, 2.71), and glycated hemoglobin (HbA1c) (βPFOS=0.03%; 95% CI: 0.002, 0.07; βPFOA=0.04%; 95% CI: 0.001, 0.07). There was no strong evidence of associations between plasma PFAS concentrations and diabetes incidence or prospective changes in glycemic indicators during the follow-up period. Conclusions: At baseline, several PFAS were cross-sectionally associated with small differences in markers of insulin secretion and β-cell function. However, there was limited evidence suggesting that PFAS concentrations are associated with diabetes incidence or changes in glycemic indicators during the follow-up period. https://doi.org/10.1289/EHP1612
Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC)
Authors: T. Zhang, M. Harrison, P. O'Donnell, A. Alva, N. Hahn, L.J. Appleman, J. Cetnar, J. Burke, M. Fleming, M. Milowsky, A. Mortazavi, N. Shore, E.V. Schmidt, C. Kresja, T. Chen, B. Bitman, R. Izumi, A. Hamdy, D.J. George
Journal: Annals of Oncology (2017)
Paclitaxel Reduces Axonal Bclw to Initiate IP3R1-Dependent Axon Degeneration
Authors: Sarah E. Pease-Raissi, Maria F. Pazyra-Murphy, Yihang Li, Franziska Wachter, Yusuke Fukuda, Sara J. Fenstermacher, Lauren A. Barclay, Gregory H. Bird, Loren D. Walensky, Rosalind A. Segal
Journal: Neuron (2017)
Ideal cardiovascular health (ICVH) in patients with a recent diagnosis of colorectal cancer (CRC)
Authors: J. Ramos, A. Álvarez-Bustos, M. Soriano, B. Nuñez, J. Ros, P. Osorio, L. Gutierrez, R. Gómez, F. Hidalgo, A. Leon, M. Mendez, C. González, A. Sanchez, S. Martínez, I. Pagola, L. Brea, C. Fiuza-Luces, A. Lucia, A. Ruiz-Casado
Journal: Annals of Oncology (2017)